[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574676":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":21,"responsibleParty":38,"collaborators":40,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"patient with metastatic prostate cancer (mPC)",null,[12,17],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Elena Guerini Rocco, MD","CONTACT","00390294372871","elena.guerinirocco@ieo.it",{"name":18,"role":14,"phone":19,"phoneExt":10,"email":20},"francesca lombardi, biologist","00390257489425","francesca.lombardi@ieo.it",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":26,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"European Institute of oncology","RECRUITING","Milan","Italy","20141",{"type":29,"coordinates":30},"Point",[31,32],9.18951,45.46427,{"lat":32,"lon":31},[35],{"name":36,"role":14,"phone":37,"phoneExt":10,"email":16},"elena Guerini Rocco, MD","+300294372871",{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[41],{"name":42,"class":43},"Pfizer","INDUSTRY","100574676",false,"NCT06762379","Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration","Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC","L2-267","Inclusion Criteria:\n\n* Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.\n\nExclusion Criteria:\n\n* Unable to provide written informed consent","MALE","18 Years",{"count":54,"type":55},125,"ESTIMATED","36 Months","OBSERVATIONAL","Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration",[60],"Metastatic Prostate Cancer (mPC)","2026-03-23",{"date":63,"type":64},"2026-03-24","ACTUAL",{"date":66,"type":64},"2024-12-20",{"date":68,"type":55},"2030-12-31",{"name":5,"class":6},1]